News Release

Update

Date: 2000/06/07

International Wex Technologies Inc. (the "company", "Wex") is pleased to report on the results of its first Advisory Board meeting. All participants had extremely relevant input and constructive suggestions. Wex has purposely chosen a diverse group of advisors from different fields that could assist the company in its total planning.

In summation, the science group suggested that Wex publish the testing results for Tetrodin in internationally recognized journals. Further the company should make an effort to make presentations at leading international conferences, symposiums and government agencies, worldwide. The scientists in attendance offered to prepare these scientific papers and make presentations.

The financial group decided to prepare a total evaluation package to include corporate structure and tax planning in the scope of Wex as an international corporate entity. They are also using their considerable contacts to bring Wex to the attention of major financial advisory groups.

The medical group was adamant that keeping Tetrodin from the market was a catastrophe for those in need of this type of non-addictive opiate drug withdrawal treatment. They encouraged Wex to review all regulatory and legal steps available to the company to commence sales of Tetrodin. The group stated that they had several independent clinical research institutes waiting to evaluate the content of the translated documentation.

The legal group recommended that the company should proceed on an expeditious basis with the application for new drug licenses by undertaking the following steps:

(a) Draft and formulate a safety application procedure designed by eminent experts for the use and application of Tetrodin in treatment of patients;

(b) Applying to the FDA (USA), HPB (Canada) and EMEA (Europe) as quickly as possible and where feasible investigate and apply under an accelerated process for new drug application.

The company thanks all participants in this 1st Advisory Board meeting and all input will be carefully weighed. Further updates will follow.

Tetrodin has been developed by the company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. The company has also begun tests on the usage of Tetrodin as a potent analgesic.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary